Sign up to save your podcasts
Or
Share C-Suite COVID-19 Challenges - Ep 3
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
C-Suite COVID-19 Challenges - Ep 3
Send us a text
Critical considerations for companies developing NASH drugs
Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES.
Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
View all episodes
By SurfingNASH.com
3.9
2424 ratings
Send us a text
Critical considerations for companies developing NASH drugs
Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES.
Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
More shows like Surfing the MASH Tsunami
View all
Freakonomics Radio
32,309 Listeners
Planet Money
30,778 Listeners
Pivot
9,758 Listeners
Diabetes Core Update
104 Listeners
The School of Greatness
21,256 Listeners
The Curbsiders Internal Medicine Podcast
3,378 Listeners
The Daily
113,432 Listeners
Up First from NPR
56,986 Listeners
The Indicator from Planet Money
9,576 Listeners
The Peter Attia Drive
8,685 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,279 Listeners
Consider This from NPR
6,472 Listeners
EASL Podcasts
0 Listeners
Docs Who Lift
419 Listeners
The Headlines
683 Listeners